Have you or someone you know been diagnosed with early Alzheimer’s Disease?
This study is enrolling patients 50-80 years of age with a diagnosis of mild cognitive impairment due to Alzheimer’s disease, or have mild Alzheimer’s dementia.
The purpose of this study is to learn more about an investigational drug called BMS-986446 to see if it could be used safely and effectively to treat Alzheimer’s disease and to test its effects on memory, thinking, and brain function.
Is this study right for me?
BMS-986446 is a new potential therapy for the treatment of early AD. It works by binding to and stopping the spread of a harmful protein called Tau. Tau protein is thought to damage and cause the death of brain cells that are important for memory, thinking, and the general ability to function in everyday life.
Patients must have a confirmed diagnosis and evidence of brain amyloid pathology.
This study will need a study partner that is a person in your life with whom you spend sufficient time on a regular basis and can provide follow-up information about you (such as a spouse, caregiver, or an adult child).
To see if you qualify, call Neurovations at 707-252-9606 or fill out the form below and we will reach out to you shortly.
Why take part in a study?
Neurovations Research strives to uplift the lives of our community members, neighbors, and leave a lasting impact for future generations. We are dedicated to finding cures and to your health and well-being.
We're not just conducting clinical trials to test innovative new treatments; we're partnering with individuals like you who share our commitment to patient care, data reliability, and the advancement of medicine. Together, we're working tirelessly to pave the way for healthier lives worldwide.
About Neurovations Research
Neurovations Research, founded in 2010, is at the forefront of innovation in the field of pain and neuromodulation. CEO and founder Dr. Eric Grigsby has led clinical trials with more than fifty companies, partnering with industry leaders and early-stage companies in medical device (Phase I-IV) and pharmaceutical trials (Phase II-IV), including first-in-man medical device trials, double-blinded and placebo-controlled trials.
What is Alzheimer's Disease?
Alzheimer’s disease is the most common type of dementia and is a progressive disease beginning with mild memory loss and possibly leading to loss of the ability to carry on a conversation and respond to the environment. Alzheimer’s disease involves parts of the brain that control thought, memory, and language. It can seriously affect a person’s ability to carry out daily activities.
To see if you qualify, call Neurovations at 707-252-9606 or click on the link below to email us.